Literature DB >> 9725413

Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.

R R Kanagasabay1, M J Unsworth-White, G Robinson, D Bevan, G Farnsworth, E J Haxby, E E Smith.   

Abstract

Heparin is the standard anticoagulant for patients undergoing cardiopulmonary bypass. There are some patients for whom heparin is unsuitable and ancrod (a defibrinogenating enzyme) has been used as an alternative. We present a patient with heparin-induced thrombocytopenia in whom treatment ancrod was ineffective. The addition of danaparoid sodium (a heparinoid) allowed safe cardiopulmonary bypass. We discuss the reasons for this and suggest that the combination of ancrod and danaparoid sodium is a logical one in such cases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725413     DOI: 10.1016/s0003-4975(98)00511-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Why is the platelet count low: should I be concerned about heparin-induced thrombocytopenia?

Authors:  Christopher Lancaster; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

Review 2.  Danaparoid: a review of its use in thromboembolic and coagulation disorders.

Authors:  Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.